US Patent 10,342,810 Scope and Claims: What It Covers, How Broad It Is, and the U.S. Patent Landscape Around Its Method-of-Treatment Claims
Executive summary: United States Patent 10,342,810 is centered on method-of-treatment claims that cover administering a compound defined by a “formula” to treat sleep disorders (including insomnia) and mood disorders (including depression), including postnatal depression, with additional claim coverage for oral administration and pharmaceutical compositions comprising the formula compound and excipients. The enforceable claim scope is driven by (i) the definition of the formula compound (not provided in your prompt), (ii) whether infringement is performed via use of the method or manufacture/sale under induced use theories, and (iii) whether competitors can design around by avoiding administration for the claimed indications (sleep/mood, insomnia, depression, postnatal depression) or by using non-formula compounds.
Which compounds does US 10,342,810’s “formula” cover and how does that define infringement risk?
Featured answer: Claim coverage hinges on the exact identity and boundaries of the “compound of the formula”. Without the formula definition, the patent’s real-world scope cannot be fully bounded. In practice, the formula definition typically controls whether a competitor’s chemical entity literally falls within the claim or is only arguable under doctrine-of-equivalents.
What the claims require at a high level
All independent claim families (method-only and composition-assisted) share a core requirement:
- A human subject “in need thereof”
- Administration of a therapeutically effective amount
- Of a compound of the formula
- For treating:
- Sleep disorder (claim 2: insomnia)
- Mood disorder (claim 4: depression)
- Postnatal depression (claim 13–16)
Practical implication for competitors
A generic or follow-on developer risks infringement if it:
- Manufactures a compound that falls within the “formula” definition; and
- Induces clinicians to administer for the claimed indications (or directly practices the method).
Design-around levers usually fall into one or more of these buckets:
- Chemical design-around: choose a compound outside the formula definition.
- Indication design-around: avoid administration for insomnia/depression/postnatal depression as claimed.
- Dosage regimen design-around: if the patent’s specification limits “therapeutically effective” via specific dosing ranges or titration schedules, competitors may argue non-equivalence to those ranges (depends on specification).
- Route design-around: claims expressly include oral administration in dependent claims; non-oral routes may reduce risk for those dependent claims (but do not eliminate risk for broader independent claims that do not require oral route).
What sleep and mood disorder indications are claimed by US 10,342,810?
Featured answer: The patent claims treatment methods for sleep disorders (including insomnia) and mood disorders (including depression), and it has dedicated coverage for postnatal depression.
Claim-by-claim indication map
- Claim 1: Treat a sleep disorder or a mood disorder using the formula compound.
- Claim 2: Sleep disorder is insomnia.
- Claim 4: Mood disorder is depression.
- Claim 13: Postnatal depression.
- Claims 3, 5, 6, 9, 11, 14, 15, 16: Dependent claims tie specific indication and administration details to the same core compound.
Scope nuance: “sleep disorder or mood disorder”
The independent claims are written in a way that can capture:
- Sleep-focused uses (insomnia)
- Mood-focused uses (depression)
- A specific subset (postnatal depression)
That structure increases the number of plausible infringement theories if the formula compound is clinically positioned across multiple psychiatry/sleep labels.
How broad are the method-of-treatment claims in US 10,342,810 (independent vs dependent)?
Featured answer: Claim 1 is the broadest independent “method” hook because it does not limit route or formulation, and it covers both sleep and mood disorders at the class level. Dependent claims narrow scope by adding specific indications (insomnia, depression, postnatal depression) and by adding oral administration and composition language.
Independent claim 1: “method of treating a sleep disorder or a mood disorder”
- No limitation in your provided claim text on route.
- No explicit limitation in your provided claim text on formulation type.
- It only requires administering a therapeutically effective amount of the formula compound.
Independent claim 7: method with a composition
Claim 7 adds a formulation wrapper:
- “Administering … a pharmaceutical composition comprising”:
- therapeutically effective amount of formula compound
- pharmaceutically acceptable excipient
- Still covers sleep and mood disorder at the independent level.
This tends to give the patentee two litigation angles:
- “Use” angle for method claims using administration of the compound
- “Composition” angle for pharmaceutical product forms
Dependent narrowing via oral administration
- Claim 6: oral administration for claim 1’s method
- Claim 12: oral administration for claim 7’s composition-based method
- Claim 14: oral administration for postnatal depression method
- Claim 16: oral administration for postnatal depression composition method
If competitors pursue non-oral delivery, they can aim to avoid dependent claim infringement, but independent claim 1 and claim 7 may still be asserted unless the claim construction or specification imposes implicit oral limitations (not stated in your prompt).
What is the scope of “pharmaceutical composition” coverage in US 10,342,810?
Featured answer: Claim 7 and claims 15–16 cover administering a composition consisting of the formula compound plus a pharmaceutically acceptable excipient, where the “administering” act is still the infringement event.
Composition language: what it does and does not capture
Based on your provided claim text:
- There is no requirement that the composition be a particular dosage form (tablet, capsule, solution) beyond “administered orally” in dependent claims.
- There is no requirement that the excipient be any specific excipient class.
- The excipient is generic: “pharmaceutically acceptable excipient.”
That generic excipient language can make it difficult to avoid infringement if the accused product still administers the formula compound for the claimed indications.
Route sensitivity
- The broad “composition” claim does not explicitly require oral route (unless interpreted through dependent claims only).
- If a competitor has a non-oral dosage form, it can reduce risk for dependent claims with explicit oral language.
How does US 10,342,810 treat postnatal depression differently from general depression?
Featured answer: Claim 13–16 create a dedicated postnatal depression method-of-treatment subset, which can matter for label targeting and for proving infringement tied to specific patient populations.
Infringement strategy implications
Postnatal depression can be treated with:
- antidepressant agents
- psychosocial approaches
- adjunctive therapies
If the formula compound is used clinically specifically for postnatal depression (and the product’s prescribing patterns align with “in need thereof”), the postnatal claims create a clearer path for assertion than general depression, particularly when competitors carve out “depression” but not “postnatal depression.”
What patent landscape typically surrounds a method-of-treatment claim like US 10,342,810 in the U.S.?
Featured answer: In the U.S., a method-of-treatment claim like this is commonly part of a broader estate that includes at least one of: chemical entity claims, process/manufacturing claims, formulation/dosage form claims, and additional method-of-use claims with different indication or dosing limitations. Enforcement often occurs via Orange Book-linked use claims (where applicable) and by litigation targeting branded and generic users.
Where this claim fits in common filing architectures
Given your claim set is method-of-use and composition-administering, the broader estate often includes:
- Compound (structure) claims: cover the chemical “of the formula”
- Salt/solvate or polymorph claims: cover specific physical forms
- Dosage form claims: tablets/capsules, controlled release, etc.
- Method-of-use claims: broader depression/anxiety/sleep, plus subtypes such as insomnia and postnatal depression
- Combination claims: if the formula compound is used with other drugs
Litigation leverage
Method claims can be asserted even when the competitor’s label is narrowly written, depending on:
- Evidence of off-label promotion/inducement
- Evidence of actual administration for the claimed indications
What are the key claim construction and infringement questions for US 10,342,810?
Featured answer: The two highest-impact issues are (1) construction of “compound of the formula” and (2) proof that administration was for a claimed disorder (insomnia, depression, postnatal depression), in a human “in need thereof,” in a therapeutically effective amount.
1) “Compound of the formula”
- Literal infringement requires the accused compound to fall within the formula.
- If boundary terms exist (substituent ranges, stereochemistry, tautomers, salts), these drive validity/infringement arguments.
2) “Therapeutically effective amount”
Courts typically treat this as a functional limitation:
- If the accused dosing produces therapeutic effect for the claimed disorder, it supports infringement.
- Competitors can try to rebut with non-therapeutic dosing or lack of clinical efficacy, but that is fact-intensive and depends on evidence.
3) “In need thereof”
This goes to patient selection:
- If the prescribing indicates the patient has insomnia/depression/postnatal depression, the element is often satisfied.
- If the compound is prescribed for other disorders, the element is harder to prove.
When do method-of-treatment patents like US 10,342,810 expire and how does that affect generic entry risk?
Featured answer: Expiration is determined by the patent’s U.S. filing and priority dates, with possible patent term adjustments and exclusivity overlays depending on whether the compound is tied to a particular approved product. The claims you provided do not include filing/priority data, so a specific expiration date cannot be computed from your prompt.
Generic entry risk drivers
For a method-of-treatment patent, generic entry risk typically increases when:
- The generic launches with labeling that includes the claimed indications; or
- The branded and generic products are used in the real world in a way that maps to the claimed method.
What Paragraph IV and Hatch-Waxman dynamics apply to US 10,342,810?
Featured answer: Paragraph IV challenges typically target patents listed in the Orange Book for an approved drug product. For method-of-treatment claims, the listing status depends on the FDA listing practices and the product’s approved labeling.
Orange Book linkage matters
If a patent like this is listed for a listed drug:
- A generic applicant can file a Paragraph IV certification challenging it.
- The patentee can seek a 30-month stay (if the statutory conditions are met).
If it is not Orange Book-listed for a particular NDA/ANDA:
- Litigation may still occur, but the Hatch-Waxman procedural stay mechanics may not attach to that product.
Which companies are likely to be relevant to the infringement and licensing strategy around US 10,342,810?
Featured answer: Without the patent’s assignee and the “compound of the formula” identity (active ingredient), no defensible company mapping can be produced from the claim text alone.
What typically gets litigated
In estates with method-of-use claims like these, the usual parties include:
- Branded product sponsor (assignee/licensor)
- ANDA applicants producing generics of the formula compound
- Distribution partners and marketing entities in inducement cases
But identifying them requires the patent record fields (assignee, listed products, chemical name, related filings) that are not present in your prompt.
How strong is US 10,342,810’s patent estate for enforcement based on the claim set alone?
Featured answer: Based solely on your claim text, the patent has a clean, litigation-friendly structure:
- It targets clinically recognizable indications (insomnia, depression, postnatal depression).
- It uses functional “therapeutically effective amount” language.
- It includes both compound administration and composition-administering variants.
Strengths
- Broad indication coverage at independent level (sleep disorder or mood disorder).
- Subtype specificity in dependents (insomnia, depression, postnatal depression).
- Oral administration dependents match common real-world delivery forms.
Potential vulnerabilities (claim-text level)
- Overbreadth risk if “formula compound” covers many variants but clinical examples in the spec are narrow.
- Functional limitation “therapeutically effective amount” can become a validity/infringement battleground if the spec does not support broad efficacy.
Key table: claim coverage map for US 10,342,810
| Claim |
What’s being claimed (method scope) |
Indication |
Route limitation |
Product/form limitation |
| 1 |
Administer therapeutically effective amount of formula compound |
Sleep disorder or mood disorder |
Not stated |
Not stated |
| 2 |
Claim 1 method |
Insomnia |
Not stated |
Not stated |
| 4 |
Claim 1 method |
Depression |
Not stated |
Not stated |
| 6 |
Claim 1 method |
Sleep or mood disorder |
Oral |
Not stated |
| 7 |
Administer pharmaceutical composition with formula compound + excipient |
Sleep disorder or mood disorder |
Not stated |
Composition required |
| 8 |
Claim 7 method |
Sleep disorder |
Not stated |
Composition required |
| 9 |
Claim 8 method |
Insomnia |
Not stated |
Composition required |
| 11 |
Claim 10 method |
Depression |
Not stated |
Composition required |
| 12 |
Claim 7 method |
Sleep or mood disorder |
Oral |
Composition required |
| 13 |
Postnatal depression method using formula compound |
Postnatal depression |
Not stated |
Not stated |
| 14 |
Claim 13 method |
Postnatal depression |
Oral |
Not stated |
| 15 |
Postnatal depression method using composition with formula + excipient |
Postnatal depression |
Not stated |
Composition required |
| 16 |
Claim 15 method |
Postnatal depression |
Oral |
Composition required |
What generic entry scenarios create the highest risk under US 10,342,810?
Featured answer: The highest risk scenario is a competitor launching a generic of the formula compound where the labeling and actual prescribing cover insomnia, depression, or postnatal depression, including oral products.
Risk-ranked scenarios
- ANDA generic + oral product label includes insomnia/depression/postnatal depression
Likely fits claim 1 and/or claim 2/4/13; and dependent oral claims 6/12/14/16.
- ANDA generic + off-label but widespread clinical use for those indications with evidence of induced prescribing
Can still support method infringement theories.
- ANDA generic with label carved away from the claimed indications and limited real-world use
Lowers infringement probability but does not eliminate if actual administration maps to the claims.
How does US 10,342,810 compare with typical U.S. method-of-use sleep/mood patents?
Featured answer: It follows a common structure: broad indication method at independent level plus clinically specific dependents. The inclusion of postnatal depression is a differentiator that tightens claim coverage for a high-specificity patient subset.
Distinguishing feature
- Many sleep/mood method patents stop at depression or insomnia broadly.
- Postnatal depression is often narrower and can be harder for competitors to avoid if they target postpartum populations.
Key Takeaways
- US 10,342,810 is a method-of-treatment patent covering administration of a “compound of the formula” for sleep disorders (insomnia) and mood disorders (depression), including postnatal depression.
- Claim scope is primarily controlled by the undefined “compound of the formula” boundaries and by proof of administration for the claimed disorders at therapeutically effective amounts.
- Dependent claims add oral administration and composition-with-excipient administration, expanding enforceability against oral dosage forms containing the formula compound.
- Generic entry risk is highest when a competitor’s product is used (and/or labeled) for insomnia, depression, or postnatal depression, especially via oral administration.
FAQs
1) Can US 10,342,810 be infringed by a non-oral dosage form?
Dependent claims explicitly requiring oral administration (claims 6, 12, 14, 16) may not be implicated by non-oral products, but independent method claims (claims 1 and 7) can still be asserted depending on claim construction and the administration route.
2) Does “pharmaceutically acceptable excipient” limit the composition claim?
No. The excipient is broadly defined, so composition avoidance generally requires changing the underlying “formula compound” rather than swapping excipients.
3) Is off-label prescribing a risk for a generic under a method-of-use patent like this?
Yes. Method-of-use claims can be asserted based on actual administration for the claimed indications, including under inducement-style theories, depending on the evidence.
4) What makes postnatal depression claims strategically important?
Postpartum-focused prescribing patterns can map more directly to a dedicated claim subset (claims 13–16), reducing ambiguity versus general depression.
5) What determines whether a Paragraph IV challenge is procedurally available?
Whether the patent is listed in the Orange Book for a specific approved drug and the ANDA/NDA certification framework tied to that listed patent.
References
- U.S. Patent No. 10,342,810. United States Patent and Trademark Office. (Claims provided in prompt).
